India’s first COVID-19 vaccine gets DCGI’s approval for human trials: Report

Life Style 

Hyderabad, June 30 — India’s first homegrown Covid-19 vaccine candidate COVAXIN has received approval from Drug Controller General of India (DCGI) to conduct Phase I and II human trials, said a media report.

COVAXIN has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), a Times Now report said.The SARS-CoV-2 strain was isolated at the National Institute of Virology (NIV) and transferred to Bharat Biotech.The Drug Controller General of India – CDSCO, Ministry of Health & Family Welfare, granted permission to start phase I and phase II of human trials after the company showed the preclinical studies, demonstrating safety and effective immune response.The company said the results from preclinical tests showed extensive safety and effective immune responses.”Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic. Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India’s strength in handling the future pandemics,” the report quoted Mrs Suchitra Ella, Joint Managing Director as saying.The company has a proven track record in developing vaccines for polio, rabies, rotavirus, Japanese Encephalitis, Chikungunya and Zika.For any query with respect to this article or any other content requirement, please contact Editor at
India Blooms

Related posts